Trimethobenzamide hydrochloride
Trimethobenzamide hydrochloride Brand names, Trimethobenzamide hydrochloride Analogs
Trimethobenzamide hydrochloride Brand Names Mixture
- Alphasel tablets (calcium phosphate [dibasic] + cobalt sulfate + D-alpha tocopheryl acetate + selenium sulfide)
- Previte (neomycin sulfate + selenium sulfide + streptomycin sulfate + vitamin A + vitamin D + vitamin E + vitamin K1)
Trimethobenzamide hydrochloride Chemical_Formula
C14H12N6O
Trimethobenzamide hydrochloride RX_link
No information avaliable
Trimethobenzamide hydrochloride fda sheet
Trimethobenzamide hydrochloride msds (material safety sheet)
Trimethobenzamide hydrochloride Synthesis Reference
No information avaliable
Trimethobenzamide hydrochloride Molecular Weight
280.285 g/mol
Trimethobenzamide hydrochloride Melting Point
No information avaliable
Trimethobenzamide hydrochloride H2O Solubility
No information avaliable
Trimethobenzamide hydrochloride State
Solid
Trimethobenzamide hydrochloride LogP
2.759
Trimethobenzamide hydrochloride Dosage Forms
Intravenous (loading dose of 12 to 24 micrograms/kg over 10 minutes followed by a continuous infusion of 0.05 to 0.2 micrograms/kg per minute, adjusted according to response)
Trimethobenzamide hydrochloride Indication
For short term treatment of acutely decompensated severe chronic heart failure (CHF).
Trimethobenzamide hydrochloride Pharmacology
Levosimendan is a new Ca2+-sensitizing inotropic agent. Ca2+ sensitizers represent a new class of inotropic agents, which overcome the disadvantages associated with currently available inotropic agents in as they are not associated with an increased risk of arrhythmias, cell injury and death due to Ca2+ overload in myocardial cells; they do not increase the activation energy; and they have the potential to reverse contractile dysfunction under pathophysiologic conditions, such as acidosis or myocardial stunning. Levosimendan has not been approved for use in the U.S. or Canada.
Trimethobenzamide hydrochloride Absorption
The bioavailability of oral levosimendan is 85 ± 6% in healthy volunteers and 84 ± 4% in patients.
Trimethobenzamide hydrochloride side effects and Toxicity
No information avaliable
Trimethobenzamide hydrochloride Patient Information
No information avaliable
Trimethobenzamide hydrochloride Organisms Affected
Humans and other mammals
